Results 41 to 50 of about 3,965 (158)

The Effectiveness and Safety of Adjuvant Therapy with t-PA in Acute Ischemic Stroke: A Systematic Review and Network Meta-Analysis

Journal of Clinical Question
Introduction: Acute ischemic stroke (AIS) is a leading cause of disability and death worldwide. While tissue plasminogen activator (t-PA) remains a cornerstone of treatment, its efficacy is limited by risks such as intracranial hemorrhage (ICH).
Xiaoju Zhen, Meng Zhao, Toshiyuki Kawashima   +2 more
doaj   +1 more source

Eptifibatide Cost Containment/Waste Minimization Strategy

, 2005
Des Peres Hospital is a community teaching hospital that performs approximately 77 percutaneous coronary interventions (PCI) per month. Eptifibatide is the primary glycoprotein IIb/IIIa inhibitor used at Des Peres Hospital.
Michael P. Peppers, Jeff Ritter
core   +1 more source

Eptifibatide in Acute Coronary Syndrome

, 2014
Background: Eptifibatide is a glycoprotein IIb/IIIa inhibitor indicated for use in acute coronary syndrome (ACS), including patients who are medically managed or undergo percutaneous coronary intervention (PCI).
Stevens, Brooke, Dugdale, Erica
core   +1 more source

Comparison between Bolus Intracoronary versus Bolus Intravenous Injection Regimens of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Anterior ST-Segment Elevation Myocardial Infarction

Рациональная фармакотерапия в кардиологии, 2019
Background. Eptifibatide achieves high local concentration via direct intracoronary (I/V) injection as it promotes clot disaggregation, but it remains unclear if it is of superior benefit than the routine intravenous (I/V) administration. Aim.
Mohamed Hassan Nab, Shaimaa Mostafa, Khaled Elrabat, Hamza Kabil, Neama Elmelegy   +4 more
doaj   +1 more source

A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules

Scientific Reports, 2022
A specific labeling strategy for bioactive molecules is presented for eptifibatide (integrilin) an antiplatelet aggregation inhibitor, which derives from the disintegrin protein barbourin in the venom of certain rattlesnakes. By specifically labeling the
Max Fleckenstein, Kevin Herr, Franziska Theiß, Stephan Knecht, Laura Wienands, Martin Brodrecht, Michael Reggelin, Gerd Buntkowsky   +7 more
doaj   +1 more source

Adjunctive intravenous argatroban or eptifibatide for ischemic stroke [PDF]

BACKGROUND: Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear. METHODS: We
et al.,, Panagos, Peter, Pizzella, Stephanie, Adeoye, Opeolu   +3 more
core   +1 more source

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction

Journal of Tehran University Heart Center, 2015
Background: Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
MohammadHasan Namazi, Morteza Safi, Hosein Vakili, Habibollah Saadat, Esfandiar Karimi, Ramin Khameneh-Bagheri   +5 more
doaj  

Platelet aggregation inhibition by Eptifibatide versus high dose Tirofiban during primary percutaneous interventions

The Egyptian Heart Journal, 2014
Background: Platelet aggregation occurs as a central role in acute coronary syndrome (ACS), and glycoprotein GP IIb/IIIa inhibitors may enhance the benefits expected from early recanalisation. Aim: To compare the degree of platelet aggregation inhibition
Yasser Sadek Nassar, Mohamed Laimud, Mohamed Afify, Mohamed Ashraf Shawky   +3 more
doaj   +1 more source

Glycoprotein IIb/IIIa Receptor Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention

Рациональная фармакотерапия в кардиологии, 2020
Recently, there has been a positive trend to reduce mortality from myocardial infarction. One of the reasons for such dynamics is the development of angiographic service in our country and the increase in the number of primary percutaneous coronary ...
A. S. Tereshchenko, Е. V. Merkulov, A. M. Samko   +2 more
doaj   +1 more source

Relation of Level of Platelet Inhibition after Eptifibatide with Major Cardiovascular Events in ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Majalah Kardiologi Indonesia, 2015
Background: Eptifibatide, an inhibitor of glycoprotein IIb/IIIa administered as adjunctive therapy to reperfusion therapy Primary PCI in STEMI patients.
Elisa Feriyanti Pakpahan, Sunarya Soerianata, Nur Haryono   +2 more
doaj   +1 more source